CJC-1295 / Ipamorelin: Two Signals, One Pulse

The short version

CJC-1295 and ipamorelin are two different research peptides, commonly stacked together. CJC-1295 mimics growth-hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to make growth hormone (GH). Ipamorelin works through a separate door: the ghrelin receptor, the same one activated by the 'hunger hormone.'

Because they act on two independent receptors on the same pituitary cell, the idea behind stacking them is that the combined GH pulse is larger than either compound alone produces by itself.

Neither compound is approved for human use. Both are sold as research chemicals, and the fixed combination itself has never been tested in a controlled human trial — everything known about the pair is inferred from studying each half separately. This page reports what the literature shows about each half and about the mechanism connecting them. It does not recommend a dose.

What it is

CJC-1295 in this combination is usually the DAC (long-acting) or no-DAC (short-acting, 'Modified GRF 1-29') form of the tetra-substituted GHRH(1-29) analog described on the CJC-1295 page. Ipamorelin is a synthetic five-amino-acid peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, selective for the GHS-R1a receptor — the ghrelin receptor.

'Selective' is the operative word. Older GH-releasing peptides (GHRP-2, GHRP-6) also trigger cortisol and prolactin release as a side effect of hitting the same receptor family broadly. Ipamorelin was designed to avoid that — in preclinical work it releases GH with markedly less effect on cortisol and prolactin.

How it works

CJC-1295 binds the GHRH receptor; ipamorelin binds GHS-R1a. These are two separate G-protein-coupled receptors on the same pituitary somatotroph cell, signaling through different second messengers — cAMP for GHRH-R, calcium for GHS-R1a.

In a cell-based receptor study, activating both receptor types together produced a cAMP response roughly double that of activating the GHRH receptor alone — direct evidence of cross-talk between the two pathways at the receptor level ^[9]. That finding is the mechanistic basis for stacking a GHRH analog with a ghrelin-receptor agonist: independent inputs converging on the same GH-release machinery, rather than one drug doing the same job twice.

What the research shows

No controlled human trial has tested the fixed CJC-1295 + ipamorelin combination. What exists is component-level evidence plus mechanism.

A 2026 meta-analysis of five randomized trials found the GHRH analog tesamorelin — the same drug class as the CJC-1295 half of this stack — reduced visceral fat by 27.71 cm², reduced hepatic fat by 4.28 percentage points, and increased lean mass by 1.42 kg, with no serious adverse events ^[6]. It is read-across evidence for what GHRH-pathway stimulation does, not direct evidence for this combination.

A broader review of GH secretagogues found the class generally well tolerated, with the main safety signal being reduced insulin sensitivity and higher blood glucose; long-term cancer and mortality data are still missing ^[7].

The CJC-1295 half's own pharmacology — GH elevated 2- to 10-fold for six or more days, IGF-1 elevated for 9 to 28 days — comes from single-agent dosing studies, not from the combination ^[4]. The albumin-binding DAC chemistry that gives long-acting CJC-1295 its multi-day action was characterized in rat studies ^[8]. The receptor cross-talk finding described above supplies the mechanistic case for synergy ^[9].

Reported effects, cautions & safety

Reported benefits (anecdotal, not clinical evidence): Deeper, more restorative sleep is the most cited benefit of this stack — often noticed within the first one to two weeks. Faster training recovery and less soreness follow close behind. Some users report gradual fat loss and a leaner look after several weeks, almost always alongside diet and training changes. Increased appetite shortly after dosing is common — expected, since ipamorelin acts on the same receptor as the hunger hormone. Improved mood and energy are reported by a subset; others notice nothing in this domain.

Reported adverse effects (anecdotal, not clinical evidence): Injection-site redness, itching, or mild swelling is the most consistently mentioned complaint. Water retention, a brief facial flush or head-rush after dosing, tingling or numbness in the hands, and occasional grogginess or lightheadedness are also described. None of this is from a controlled trial.

Cited safety cautions: The fixed blend has never been tested as a blend — everything is inferred from the two halves separately, and their pharmacokinetics do not match: CJC-1295 DAC runs for days, ipamorelin clears in hours ^[4][8][9]. GH secretagogues as a class carry a glucose and insulin-sensitivity signal ^[7]. Sustained GH/IGF-1 elevation is a mechanism-based concern for anyone with an active or prior malignancy, since IGF-1 promotes cell proliferation ^[7]. Fluid retention, joint discomfort, and carpal-tunnel-type nerve symptoms are the expected downstream effects of GH-driven sodium and water retention ^[7].

Where it fits in the GH axis

This combination sits between the other two compounds on this desk. CJC-1295 alone supplies the long-acting GHRH signal; adding ipamorelin brings in a second, independent pathway aimed at amplifying the same GH pulse. Against tesamorelin — the one FDA-approved GHRH analog here, with a real clinical trial record — this stack is the unregulated, dual-receptor counterpart with no trial of its own. Reading the three together shows the range: a single GHRH signal, a two-receptor stack, and an approved comparator. See the comparison page.